RxDoctor Payments Data

Shannon Green, MD

Obstetrics & Gynecology · Washington, DCNPI 1720254261

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.1% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations.

$1,936in general payments, 2019–2025

Across 90 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$403
  • Astellas Pharma US Inc$328
  • Hologic Sales And Service, LLC$165
  • Bayer$149
  • Pfizer$131
  • Astellas Pharma Global Development$118
  • plus $640 from 18 others

What the payments were for

  • Food & beverage$1,80193%
  • Education$1347%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,936 in reported general payments places this provider in the 85th percentile of 195 obstetrics & gynecology providers in District of Columbia.

See all obstetrics & gynecology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$28,254
Medicare patients
244
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab14$23,836
PremarinEstrogens, Conjugated27$15,565
EstringEstradiol21$11,002
Estradiol108$9,638
YuvafemEstradiol21$4,039
DottiEstradiol17$1,896
Estradiol (Twice Weekly)Estradiol14$1,742
ValacyclovirValacyclovir Hcl27$1,158
ProgesteroneProgesterone, Micronized23$801
Alendronate Sodium30$465
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$208
Betamethasone Valerate17$199
Fluconazole13$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Estring$131$26,56748 claims
AmgenProlia$15$23,83614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 obstetrics & gynecology providers in District of Columbia.

Other obstetrics & gynecology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →